All
FDA Approves Calquence for Leukemia and Lymphoma Subsets
November 21st 2019In partnership with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the Food and Drug Administration (FDA) has granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Proton Beam Therapy: A Less Toxic Option in Liver Cancer
November 21st 2019While radiation therapy may be a common alternative for inoperable hepatocellular carcinoma, two new studies suggest that proton radiation therapy may offer the same benefits as the more traditionally used photon radiation therapy, with less toxicity.
Precision Medicine and Personalized Treatments Shifting the Tide in Mantle Cell Lymphoma
November 18th 2019While resistance can often make it a challenge to treat mantle cell lymphoma, therapies have come a long way in recent years thanks to the emergence of personalized treatment and the use of BTK inhibitors, according to one expert.
Let's Win and the Elvin Howard, Sr. PCAF Raise Awareness with a New PSA
November 15th 2019The Elvin Howard, Sr. Pancreatic Cancer Advocacy Foundation (Elvin Howard, Sr. PCAF) and Let’s Win have released a new public service announcement (PSA) to raise awareness of pancreatic cancer in people of color.